Ganglioneuroblastoma

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 741 Experts worldwide ranked by ideXlab platform

Kazuhiro Takahashi - One of the best experts on this subject based on the ideXlab platform.

  • expression of melanin concentrating hormone receptor messenger ribonucleic acid in tumor tissues of pheochromocytoma Ganglioneuroblastoma and neuroblastoma
    The Journal of Clinical Endocrinology and Metabolism, 2001
    Co-Authors: Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Fumitoshi Satoh, Yutaka Hayashi, Hironobu Sasano, Tomomi Kitamuro, Takao Noshiro, Shigeki Shibahara
    Abstract:

    Expression of melanin-concentrating hormone (MCH) receptor messenger ribonucleic acid (mRNA) was studied by RT-PCR and Northern blot analysis in human brain; pituitary; adrenal glands; tumor tissues of adrenal tumors, Ganglioneuroblastomas, and neuroblastomas; and various cultured tumor cell lines. RT-PCR analysis showed that MCH receptor mRNA was widely expressed in brain tissues, pituitary, normal portions of adrenal glands (cortex and medulla), tumor tissues of adrenocortical tumors (12 of 13 cases), pheochromocytoma (all 7 cases), Ganglioneuroblastoma (1 case), neuroblastoma (all 5 cases), and various cultured tumor cell lines (6 of 7 cell lines), including 2 neuroblastoma cell lines. Northern blot analysis showed the expression of MCH receptor mRNA (∼2.4 kb) only in the tumor tissues of 5 pheochromocytomas, 1 Ganglioneuroblastoma, and 4 neuroblastomas, indicating that the expression levels of MCH receptor mRNA are much higher in these tumors than in the other tissues. These findings raised the possib...

  • orexin a in the human brain and tumor tissues of Ganglioneuroblastoma and neuroblastoma
    Peptides, 2000
    Co-Authors: Zenei Arihara, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Fumitoshi Satoh, Sadayoshi Ito, Yutaka Hayashi, Hironobu Sasano, Toraichi Mouri
    Abstract:

    Regional distribution of orexin-A-like immunoreactivity in the human brain and pituitary, and the presence of orexin-A-like immunoreactivity in the tumor tissues of pheochromocytomas, Ganglioneuroblastomas and neuroblastomas were studied by radioimmunoassay. Expression of orexin mRNA was studied by reverse transcriptase polymerase chain reaction (PCR) method. Orexin-A-like immunoreactivity was detected in every region of human brain, but not in the pituitary. The highest concentration of orexin-A-like immunoreactivity in the human brain was found in hypothalamus (17.8 +/- 4.3 pmol/g wet weight, mean +/- SEM, n = 7), followed by thalamus, medulla oblongata, and pons. Orexin-A-like immunoreactivity was detected in the tumor tissues of Ganglioneuroblastoma and neuroblastoma, but not in the tumor tissues of pheochromocytoma. Reverse phase high performance liquid chromatographic analyses of the orexin-A-like immunoreactivity in the human brain extracts and neuroblastoma extracts showed a single immunoreactive peak, which was eluted in an identical position to synthetic human orexin-A. Orexin mRNA was expressed in the hypothalamus and in the tumor tissues of Ganglioneuroblastoma and neuroblastoma. These findings suggest that orexin-A is produced in the hypothalamus and transported to various brain regions via axons. In addition, this study has shown for the first time the production of orexin-A by Ganglioneuroblastomas and neuroblastomas.

  • cerebellin and cerebellin mrna in the human brain adrenal glands and the tumour tissues of adrenal tumour Ganglioneuroblastoma and neuroblastoma
    Journal of Endocrinology, 1997
    Co-Authors: Fumitoshi Satoh, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Yasuji Mizuno, Yukio Miura, Sadao Takase, Yutaka Hayashi
    Abstract:

    The expression of cerebellin and cerebellin mRNA was studied by radioimmunoassay and Northern blot analysis in the human brain, adrenal gland and the tumour tissues of adrenal tumour, Ganglioneuroblastoma and neuroblastoma. Immunoreactive cerebellin was detected in every region of brain studied, with the highest concentrations found in the hemisphere of the cerebellum (424.2 +/- 12.6 pmol/g wet weight, n = 6, mean +/- S.E.M.) and the vermis of the cerebellum (256.8 +/- 30.5 pmol/g wet weight). Immunoreactive cerebellin was also detected in the pituitary (8.2 +/- 1.8 pmol/g wet weight), the spinal cord (3.3 +/- 0.3 pmol/g wet weight) and the normal parts of adrenal glands (2.98 +/- 0.37 pmol/g wet weight, n = 9) and some tumour tissues, such as phaeochromocytomas, cortisol-producing adrenocortical adenomas, Ganglioneuroblastomas and neuroblastomas. Northern blot analysis showed that cerebellin mRNA was highly expressed in the hemisphere and vermis of the cerebellum. Cerebellin mRNA was also expressed in other regions of the brain and the tumour tissues of phaeochromocytoma, cortisol-producing adrenocortical adenoma, Ganglioneuroblastoma and neuroblastoma. Immunocytochemistry of the normal adrenal gland showed that immunoreactive cerebellin was localized in the adrenal medulla. The present study has shown the expression of cerebellin and cerebellin mRNA, not only in the cerebellum but also in other regions of the brain and some tumours, such as cortisol-producing adrenocortical adenoma, phaeochromocytoma and neuroblastoma. These findings suggest possible pathophysiological roles of cerebellin peptides, not only in the cerebellum, but also in the extra-cerebellar tissues.

  • adrenomedullin in human brain adrenal glands and tumor tissues of pheochromocytoma Ganglioneuroblastoma and neuroblastoma
    The Journal of Clinical Endocrinology and Metabolism, 1995
    Co-Authors: Fumitoshi Satoh, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Yukio Miura, Y Hayashi, Keishi Abe, Hironobu Sasano
    Abstract:

    Adrenomedullin is a potent vasodilator peptide that was isolated from human pheochromocytoma. But the presence of adrenomedullin in the brain has not been clarified. We studied the presence of adrenomedullin in the human brain obtained at autopsy from 6 subjects by radioimmunoassay, as well as in the human adrenal glands and tumor tissues of pheochromocytoma, Ganglioneuroblastoma and neuroblastoma. Immunoreactive adrenomedullin was detected in every region of human brain examined (0.26-1.4 pmol/g wet weight) with the highest concentrations found in thalamus (1.40 +/- 0.39 pmol/g wet weight, mean +/- SEM) and hypothalamus (1.28 +/- 0.48 pmol/g wet weight). Reverse phase high performance liquid chromatography showed that the immunoreactive adrenomedullin in the human brain was eluted in the position of synthetic human adrenomedullin 1-52. High concentrations of immunoreactive adrenomedullin were found in human adrenal glands (12.6 +/- 1.0 pmol/g wet weight, n = 7), pheochromocytoma (4.5 +/- 1.5 pmol/g wet weight, n = 11), Ganglioneuroblastoma (2.0 +/- 1.3 pmol/g wet weight, n = 4) and neuroblastoma (0.55 +/- 0.21 pmol/g wet weight, n = 3). The present study has shown that adrenomedullin is present in the human brain in high concentrations, suggesting that adrenomedullin acts as a neurotransmitter, neuromodulator or neurohormone in man.

  • neuropeptide y as a plasma marker for phaeochromocytoma Ganglioneuroblastoma and neuroblastoma
    Clinical Science, 1992
    Co-Authors: Toraichi Mouri, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Keiichi Itoi, Y Hayashi, Sumio Hasegawa, Yukio Miura
    Abstract:

    1. We investigated the usefulness of neuropeptide Y as a plasma marker for phaeochromocytoma, Ganglioneuroblastoma and neuroblastoma using a simple and highly sensitive r.i.a. for human neuropeptide Y. 2. Plasma immunoreactive neuropeptide Y concentrations were measured without extraction in plasma samples (100 microliters) from patients with various diseases. 3. The plasma immunoreactive neuropeptide Y concentration in patients with phaeochromocytoma (172.3 +/- 132.4 pmol/l, mean +/- SD, n = 23) was significantly higher than that in healthy adult subjects (40.1 +/- 10.1 pmol/l, n = 40, P < 0.0001). The plasma immunoreactive neuropeptide Y concentrations in patients with Ganglioneuroblastoma (590.7 +/- 563.6 pmol/l, n = 6) and patients with neuroblastoma (566.9 +/- 524.4 pmol/l, n = 15) were significantly higher than those in control children (1-9 years old, 82.2 +/- 39.9 pmol/l, n = 72, P < 0.0001). 4. The plasma immunoreactive neuropeptide Y concentration in patients with essential hypertension (34.0 +/- 3.7 pmol/l, n = 18) was within the normal range, but in patients with chronic renal failure undergoing maintenance haemodialysis (192.1 +/- 68.0 pmol/l, n = 25) and in non-dialysed patients with chronic renal failure (85.1 +/- 23.1 pmol/l, n = 7) it was significantly higher than that in healthy adult subjects (P < 0.0001). 5. Eighty-seven per cent of the patients with phaeochromocytoma, 67% of the patients with Ganglioneuroblastoma and 80% of the patients with neuroblastoma showed plasma immunoreactive neuropeptide Y concentrations higher than the upper limits in the control subjects [62 pmol/l (adult) and 160 pmol/l (children)].(ABSTRACT TRUNCATED AT 250 WORDS)

Fumitoshi Satoh - One of the best experts on this subject based on the ideXlab platform.

  • expression of melanin concentrating hormone receptor messenger ribonucleic acid in tumor tissues of pheochromocytoma Ganglioneuroblastoma and neuroblastoma
    The Journal of Clinical Endocrinology and Metabolism, 2001
    Co-Authors: Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Fumitoshi Satoh, Yutaka Hayashi, Hironobu Sasano, Tomomi Kitamuro, Takao Noshiro, Shigeki Shibahara
    Abstract:

    Expression of melanin-concentrating hormone (MCH) receptor messenger ribonucleic acid (mRNA) was studied by RT-PCR and Northern blot analysis in human brain; pituitary; adrenal glands; tumor tissues of adrenal tumors, Ganglioneuroblastomas, and neuroblastomas; and various cultured tumor cell lines. RT-PCR analysis showed that MCH receptor mRNA was widely expressed in brain tissues, pituitary, normal portions of adrenal glands (cortex and medulla), tumor tissues of adrenocortical tumors (12 of 13 cases), pheochromocytoma (all 7 cases), Ganglioneuroblastoma (1 case), neuroblastoma (all 5 cases), and various cultured tumor cell lines (6 of 7 cell lines), including 2 neuroblastoma cell lines. Northern blot analysis showed the expression of MCH receptor mRNA (∼2.4 kb) only in the tumor tissues of 5 pheochromocytomas, 1 Ganglioneuroblastoma, and 4 neuroblastomas, indicating that the expression levels of MCH receptor mRNA are much higher in these tumors than in the other tissues. These findings raised the possib...

  • orexin a in the human brain and tumor tissues of Ganglioneuroblastoma and neuroblastoma
    Peptides, 2000
    Co-Authors: Zenei Arihara, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Fumitoshi Satoh, Sadayoshi Ito, Yutaka Hayashi, Hironobu Sasano, Toraichi Mouri
    Abstract:

    Regional distribution of orexin-A-like immunoreactivity in the human brain and pituitary, and the presence of orexin-A-like immunoreactivity in the tumor tissues of pheochromocytomas, Ganglioneuroblastomas and neuroblastomas were studied by radioimmunoassay. Expression of orexin mRNA was studied by reverse transcriptase polymerase chain reaction (PCR) method. Orexin-A-like immunoreactivity was detected in every region of human brain, but not in the pituitary. The highest concentration of orexin-A-like immunoreactivity in the human brain was found in hypothalamus (17.8 +/- 4.3 pmol/g wet weight, mean +/- SEM, n = 7), followed by thalamus, medulla oblongata, and pons. Orexin-A-like immunoreactivity was detected in the tumor tissues of Ganglioneuroblastoma and neuroblastoma, but not in the tumor tissues of pheochromocytoma. Reverse phase high performance liquid chromatographic analyses of the orexin-A-like immunoreactivity in the human brain extracts and neuroblastoma extracts showed a single immunoreactive peak, which was eluted in an identical position to synthetic human orexin-A. Orexin mRNA was expressed in the hypothalamus and in the tumor tissues of Ganglioneuroblastoma and neuroblastoma. These findings suggest that orexin-A is produced in the hypothalamus and transported to various brain regions via axons. In addition, this study has shown for the first time the production of orexin-A by Ganglioneuroblastomas and neuroblastomas.

  • cerebellin and cerebellin mrna in the human brain adrenal glands and the tumour tissues of adrenal tumour Ganglioneuroblastoma and neuroblastoma
    Journal of Endocrinology, 1997
    Co-Authors: Fumitoshi Satoh, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Yasuji Mizuno, Yukio Miura, Sadao Takase, Yutaka Hayashi
    Abstract:

    The expression of cerebellin and cerebellin mRNA was studied by radioimmunoassay and Northern blot analysis in the human brain, adrenal gland and the tumour tissues of adrenal tumour, Ganglioneuroblastoma and neuroblastoma. Immunoreactive cerebellin was detected in every region of brain studied, with the highest concentrations found in the hemisphere of the cerebellum (424.2 +/- 12.6 pmol/g wet weight, n = 6, mean +/- S.E.M.) and the vermis of the cerebellum (256.8 +/- 30.5 pmol/g wet weight). Immunoreactive cerebellin was also detected in the pituitary (8.2 +/- 1.8 pmol/g wet weight), the spinal cord (3.3 +/- 0.3 pmol/g wet weight) and the normal parts of adrenal glands (2.98 +/- 0.37 pmol/g wet weight, n = 9) and some tumour tissues, such as phaeochromocytomas, cortisol-producing adrenocortical adenomas, Ganglioneuroblastomas and neuroblastomas. Northern blot analysis showed that cerebellin mRNA was highly expressed in the hemisphere and vermis of the cerebellum. Cerebellin mRNA was also expressed in other regions of the brain and the tumour tissues of phaeochromocytoma, cortisol-producing adrenocortical adenoma, Ganglioneuroblastoma and neuroblastoma. Immunocytochemistry of the normal adrenal gland showed that immunoreactive cerebellin was localized in the adrenal medulla. The present study has shown the expression of cerebellin and cerebellin mRNA, not only in the cerebellum but also in other regions of the brain and some tumours, such as cortisol-producing adrenocortical adenoma, phaeochromocytoma and neuroblastoma. These findings suggest possible pathophysiological roles of cerebellin peptides, not only in the cerebellum, but also in the extra-cerebellar tissues.

  • adrenomedullin in human brain adrenal glands and tumor tissues of pheochromocytoma Ganglioneuroblastoma and neuroblastoma
    The Journal of Clinical Endocrinology and Metabolism, 1995
    Co-Authors: Fumitoshi Satoh, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Yukio Miura, Y Hayashi, Keishi Abe, Hironobu Sasano
    Abstract:

    Adrenomedullin is a potent vasodilator peptide that was isolated from human pheochromocytoma. But the presence of adrenomedullin in the brain has not been clarified. We studied the presence of adrenomedullin in the human brain obtained at autopsy from 6 subjects by radioimmunoassay, as well as in the human adrenal glands and tumor tissues of pheochromocytoma, Ganglioneuroblastoma and neuroblastoma. Immunoreactive adrenomedullin was detected in every region of human brain examined (0.26-1.4 pmol/g wet weight) with the highest concentrations found in thalamus (1.40 +/- 0.39 pmol/g wet weight, mean +/- SEM) and hypothalamus (1.28 +/- 0.48 pmol/g wet weight). Reverse phase high performance liquid chromatography showed that the immunoreactive adrenomedullin in the human brain was eluted in the position of synthetic human adrenomedullin 1-52. High concentrations of immunoreactive adrenomedullin were found in human adrenal glands (12.6 +/- 1.0 pmol/g wet weight, n = 7), pheochromocytoma (4.5 +/- 1.5 pmol/g wet weight, n = 11), Ganglioneuroblastoma (2.0 +/- 1.3 pmol/g wet weight, n = 4) and neuroblastoma (0.55 +/- 0.21 pmol/g wet weight, n = 3). The present study has shown that adrenomedullin is present in the human brain in high concentrations, suggesting that adrenomedullin acts as a neurotransmitter, neuromodulator or neurohormone in man.

Osamu Murakami - One of the best experts on this subject based on the ideXlab platform.

  • expression of melanin concentrating hormone receptor messenger ribonucleic acid in tumor tissues of pheochromocytoma Ganglioneuroblastoma and neuroblastoma
    The Journal of Clinical Endocrinology and Metabolism, 2001
    Co-Authors: Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Fumitoshi Satoh, Yutaka Hayashi, Hironobu Sasano, Tomomi Kitamuro, Takao Noshiro, Shigeki Shibahara
    Abstract:

    Expression of melanin-concentrating hormone (MCH) receptor messenger ribonucleic acid (mRNA) was studied by RT-PCR and Northern blot analysis in human brain; pituitary; adrenal glands; tumor tissues of adrenal tumors, Ganglioneuroblastomas, and neuroblastomas; and various cultured tumor cell lines. RT-PCR analysis showed that MCH receptor mRNA was widely expressed in brain tissues, pituitary, normal portions of adrenal glands (cortex and medulla), tumor tissues of adrenocortical tumors (12 of 13 cases), pheochromocytoma (all 7 cases), Ganglioneuroblastoma (1 case), neuroblastoma (all 5 cases), and various cultured tumor cell lines (6 of 7 cell lines), including 2 neuroblastoma cell lines. Northern blot analysis showed the expression of MCH receptor mRNA (∼2.4 kb) only in the tumor tissues of 5 pheochromocytomas, 1 Ganglioneuroblastoma, and 4 neuroblastomas, indicating that the expression levels of MCH receptor mRNA are much higher in these tumors than in the other tissues. These findings raised the possib...

  • orexin a in the human brain and tumor tissues of Ganglioneuroblastoma and neuroblastoma
    Peptides, 2000
    Co-Authors: Zenei Arihara, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Fumitoshi Satoh, Sadayoshi Ito, Yutaka Hayashi, Hironobu Sasano, Toraichi Mouri
    Abstract:

    Regional distribution of orexin-A-like immunoreactivity in the human brain and pituitary, and the presence of orexin-A-like immunoreactivity in the tumor tissues of pheochromocytomas, Ganglioneuroblastomas and neuroblastomas were studied by radioimmunoassay. Expression of orexin mRNA was studied by reverse transcriptase polymerase chain reaction (PCR) method. Orexin-A-like immunoreactivity was detected in every region of human brain, but not in the pituitary. The highest concentration of orexin-A-like immunoreactivity in the human brain was found in hypothalamus (17.8 +/- 4.3 pmol/g wet weight, mean +/- SEM, n = 7), followed by thalamus, medulla oblongata, and pons. Orexin-A-like immunoreactivity was detected in the tumor tissues of Ganglioneuroblastoma and neuroblastoma, but not in the tumor tissues of pheochromocytoma. Reverse phase high performance liquid chromatographic analyses of the orexin-A-like immunoreactivity in the human brain extracts and neuroblastoma extracts showed a single immunoreactive peak, which was eluted in an identical position to synthetic human orexin-A. Orexin mRNA was expressed in the hypothalamus and in the tumor tissues of Ganglioneuroblastoma and neuroblastoma. These findings suggest that orexin-A is produced in the hypothalamus and transported to various brain regions via axons. In addition, this study has shown for the first time the production of orexin-A by Ganglioneuroblastomas and neuroblastomas.

  • cerebellin and cerebellin mrna in the human brain adrenal glands and the tumour tissues of adrenal tumour Ganglioneuroblastoma and neuroblastoma
    Journal of Endocrinology, 1997
    Co-Authors: Fumitoshi Satoh, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Yasuji Mizuno, Yukio Miura, Sadao Takase, Yutaka Hayashi
    Abstract:

    The expression of cerebellin and cerebellin mRNA was studied by radioimmunoassay and Northern blot analysis in the human brain, adrenal gland and the tumour tissues of adrenal tumour, Ganglioneuroblastoma and neuroblastoma. Immunoreactive cerebellin was detected in every region of brain studied, with the highest concentrations found in the hemisphere of the cerebellum (424.2 +/- 12.6 pmol/g wet weight, n = 6, mean +/- S.E.M.) and the vermis of the cerebellum (256.8 +/- 30.5 pmol/g wet weight). Immunoreactive cerebellin was also detected in the pituitary (8.2 +/- 1.8 pmol/g wet weight), the spinal cord (3.3 +/- 0.3 pmol/g wet weight) and the normal parts of adrenal glands (2.98 +/- 0.37 pmol/g wet weight, n = 9) and some tumour tissues, such as phaeochromocytomas, cortisol-producing adrenocortical adenomas, Ganglioneuroblastomas and neuroblastomas. Northern blot analysis showed that cerebellin mRNA was highly expressed in the hemisphere and vermis of the cerebellum. Cerebellin mRNA was also expressed in other regions of the brain and the tumour tissues of phaeochromocytoma, cortisol-producing adrenocortical adenoma, Ganglioneuroblastoma and neuroblastoma. Immunocytochemistry of the normal adrenal gland showed that immunoreactive cerebellin was localized in the adrenal medulla. The present study has shown the expression of cerebellin and cerebellin mRNA, not only in the cerebellum but also in other regions of the brain and some tumours, such as cortisol-producing adrenocortical adenoma, phaeochromocytoma and neuroblastoma. These findings suggest possible pathophysiological roles of cerebellin peptides, not only in the cerebellum, but also in the extra-cerebellar tissues.

  • adrenomedullin in human brain adrenal glands and tumor tissues of pheochromocytoma Ganglioneuroblastoma and neuroblastoma
    The Journal of Clinical Endocrinology and Metabolism, 1995
    Co-Authors: Fumitoshi Satoh, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Yukio Miura, Y Hayashi, Keishi Abe, Hironobu Sasano
    Abstract:

    Adrenomedullin is a potent vasodilator peptide that was isolated from human pheochromocytoma. But the presence of adrenomedullin in the brain has not been clarified. We studied the presence of adrenomedullin in the human brain obtained at autopsy from 6 subjects by radioimmunoassay, as well as in the human adrenal glands and tumor tissues of pheochromocytoma, Ganglioneuroblastoma and neuroblastoma. Immunoreactive adrenomedullin was detected in every region of human brain examined (0.26-1.4 pmol/g wet weight) with the highest concentrations found in thalamus (1.40 +/- 0.39 pmol/g wet weight, mean +/- SEM) and hypothalamus (1.28 +/- 0.48 pmol/g wet weight). Reverse phase high performance liquid chromatography showed that the immunoreactive adrenomedullin in the human brain was eluted in the position of synthetic human adrenomedullin 1-52. High concentrations of immunoreactive adrenomedullin were found in human adrenal glands (12.6 +/- 1.0 pmol/g wet weight, n = 7), pheochromocytoma (4.5 +/- 1.5 pmol/g wet weight, n = 11), Ganglioneuroblastoma (2.0 +/- 1.3 pmol/g wet weight, n = 4) and neuroblastoma (0.55 +/- 0.21 pmol/g wet weight, n = 3). The present study has shown that adrenomedullin is present in the human brain in high concentrations, suggesting that adrenomedullin acts as a neurotransmitter, neuromodulator or neurohormone in man.

  • neuropeptide y as a plasma marker for phaeochromocytoma Ganglioneuroblastoma and neuroblastoma
    Clinical Science, 1992
    Co-Authors: Toraichi Mouri, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Keiichi Itoi, Y Hayashi, Sumio Hasegawa, Yukio Miura
    Abstract:

    1. We investigated the usefulness of neuropeptide Y as a plasma marker for phaeochromocytoma, Ganglioneuroblastoma and neuroblastoma using a simple and highly sensitive r.i.a. for human neuropeptide Y. 2. Plasma immunoreactive neuropeptide Y concentrations were measured without extraction in plasma samples (100 microliters) from patients with various diseases. 3. The plasma immunoreactive neuropeptide Y concentration in patients with phaeochromocytoma (172.3 +/- 132.4 pmol/l, mean +/- SD, n = 23) was significantly higher than that in healthy adult subjects (40.1 +/- 10.1 pmol/l, n = 40, P < 0.0001). The plasma immunoreactive neuropeptide Y concentrations in patients with Ganglioneuroblastoma (590.7 +/- 563.6 pmol/l, n = 6) and patients with neuroblastoma (566.9 +/- 524.4 pmol/l, n = 15) were significantly higher than those in control children (1-9 years old, 82.2 +/- 39.9 pmol/l, n = 72, P < 0.0001). 4. The plasma immunoreactive neuropeptide Y concentration in patients with essential hypertension (34.0 +/- 3.7 pmol/l, n = 18) was within the normal range, but in patients with chronic renal failure undergoing maintenance haemodialysis (192.1 +/- 68.0 pmol/l, n = 25) and in non-dialysed patients with chronic renal failure (85.1 +/- 23.1 pmol/l, n = 7) it was significantly higher than that in healthy adult subjects (P < 0.0001). 5. Eighty-seven per cent of the patients with phaeochromocytoma, 67% of the patients with Ganglioneuroblastoma and 80% of the patients with neuroblastoma showed plasma immunoreactive neuropeptide Y concentrations higher than the upper limits in the control subjects [62 pmol/l (adult) and 160 pmol/l (children)].(ABSTRACT TRUNCATED AT 250 WORDS)

Kazuhito Totsune - One of the best experts on this subject based on the ideXlab platform.

  • expression of melanin concentrating hormone receptor messenger ribonucleic acid in tumor tissues of pheochromocytoma Ganglioneuroblastoma and neuroblastoma
    The Journal of Clinical Endocrinology and Metabolism, 2001
    Co-Authors: Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Fumitoshi Satoh, Yutaka Hayashi, Hironobu Sasano, Tomomi Kitamuro, Takao Noshiro, Shigeki Shibahara
    Abstract:

    Expression of melanin-concentrating hormone (MCH) receptor messenger ribonucleic acid (mRNA) was studied by RT-PCR and Northern blot analysis in human brain; pituitary; adrenal glands; tumor tissues of adrenal tumors, Ganglioneuroblastomas, and neuroblastomas; and various cultured tumor cell lines. RT-PCR analysis showed that MCH receptor mRNA was widely expressed in brain tissues, pituitary, normal portions of adrenal glands (cortex and medulla), tumor tissues of adrenocortical tumors (12 of 13 cases), pheochromocytoma (all 7 cases), Ganglioneuroblastoma (1 case), neuroblastoma (all 5 cases), and various cultured tumor cell lines (6 of 7 cell lines), including 2 neuroblastoma cell lines. Northern blot analysis showed the expression of MCH receptor mRNA (∼2.4 kb) only in the tumor tissues of 5 pheochromocytomas, 1 Ganglioneuroblastoma, and 4 neuroblastomas, indicating that the expression levels of MCH receptor mRNA are much higher in these tumors than in the other tissues. These findings raised the possib...

  • orexin a in the human brain and tumor tissues of Ganglioneuroblastoma and neuroblastoma
    Peptides, 2000
    Co-Authors: Zenei Arihara, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Fumitoshi Satoh, Sadayoshi Ito, Yutaka Hayashi, Hironobu Sasano, Toraichi Mouri
    Abstract:

    Regional distribution of orexin-A-like immunoreactivity in the human brain and pituitary, and the presence of orexin-A-like immunoreactivity in the tumor tissues of pheochromocytomas, Ganglioneuroblastomas and neuroblastomas were studied by radioimmunoassay. Expression of orexin mRNA was studied by reverse transcriptase polymerase chain reaction (PCR) method. Orexin-A-like immunoreactivity was detected in every region of human brain, but not in the pituitary. The highest concentration of orexin-A-like immunoreactivity in the human brain was found in hypothalamus (17.8 +/- 4.3 pmol/g wet weight, mean +/- SEM, n = 7), followed by thalamus, medulla oblongata, and pons. Orexin-A-like immunoreactivity was detected in the tumor tissues of Ganglioneuroblastoma and neuroblastoma, but not in the tumor tissues of pheochromocytoma. Reverse phase high performance liquid chromatographic analyses of the orexin-A-like immunoreactivity in the human brain extracts and neuroblastoma extracts showed a single immunoreactive peak, which was eluted in an identical position to synthetic human orexin-A. Orexin mRNA was expressed in the hypothalamus and in the tumor tissues of Ganglioneuroblastoma and neuroblastoma. These findings suggest that orexin-A is produced in the hypothalamus and transported to various brain regions via axons. In addition, this study has shown for the first time the production of orexin-A by Ganglioneuroblastomas and neuroblastomas.

  • cerebellin and cerebellin mrna in the human brain adrenal glands and the tumour tissues of adrenal tumour Ganglioneuroblastoma and neuroblastoma
    Journal of Endocrinology, 1997
    Co-Authors: Fumitoshi Satoh, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Yasuji Mizuno, Yukio Miura, Sadao Takase, Yutaka Hayashi
    Abstract:

    The expression of cerebellin and cerebellin mRNA was studied by radioimmunoassay and Northern blot analysis in the human brain, adrenal gland and the tumour tissues of adrenal tumour, Ganglioneuroblastoma and neuroblastoma. Immunoreactive cerebellin was detected in every region of brain studied, with the highest concentrations found in the hemisphere of the cerebellum (424.2 +/- 12.6 pmol/g wet weight, n = 6, mean +/- S.E.M.) and the vermis of the cerebellum (256.8 +/- 30.5 pmol/g wet weight). Immunoreactive cerebellin was also detected in the pituitary (8.2 +/- 1.8 pmol/g wet weight), the spinal cord (3.3 +/- 0.3 pmol/g wet weight) and the normal parts of adrenal glands (2.98 +/- 0.37 pmol/g wet weight, n = 9) and some tumour tissues, such as phaeochromocytomas, cortisol-producing adrenocortical adenomas, Ganglioneuroblastomas and neuroblastomas. Northern blot analysis showed that cerebellin mRNA was highly expressed in the hemisphere and vermis of the cerebellum. Cerebellin mRNA was also expressed in other regions of the brain and the tumour tissues of phaeochromocytoma, cortisol-producing adrenocortical adenoma, Ganglioneuroblastoma and neuroblastoma. Immunocytochemistry of the normal adrenal gland showed that immunoreactive cerebellin was localized in the adrenal medulla. The present study has shown the expression of cerebellin and cerebellin mRNA, not only in the cerebellum but also in other regions of the brain and some tumours, such as cortisol-producing adrenocortical adenoma, phaeochromocytoma and neuroblastoma. These findings suggest possible pathophysiological roles of cerebellin peptides, not only in the cerebellum, but also in the extra-cerebellar tissues.

  • adrenomedullin in human brain adrenal glands and tumor tissues of pheochromocytoma Ganglioneuroblastoma and neuroblastoma
    The Journal of Clinical Endocrinology and Metabolism, 1995
    Co-Authors: Fumitoshi Satoh, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Yukio Miura, Y Hayashi, Keishi Abe, Hironobu Sasano
    Abstract:

    Adrenomedullin is a potent vasodilator peptide that was isolated from human pheochromocytoma. But the presence of adrenomedullin in the brain has not been clarified. We studied the presence of adrenomedullin in the human brain obtained at autopsy from 6 subjects by radioimmunoassay, as well as in the human adrenal glands and tumor tissues of pheochromocytoma, Ganglioneuroblastoma and neuroblastoma. Immunoreactive adrenomedullin was detected in every region of human brain examined (0.26-1.4 pmol/g wet weight) with the highest concentrations found in thalamus (1.40 +/- 0.39 pmol/g wet weight, mean +/- SEM) and hypothalamus (1.28 +/- 0.48 pmol/g wet weight). Reverse phase high performance liquid chromatography showed that the immunoreactive adrenomedullin in the human brain was eluted in the position of synthetic human adrenomedullin 1-52. High concentrations of immunoreactive adrenomedullin were found in human adrenal glands (12.6 +/- 1.0 pmol/g wet weight, n = 7), pheochromocytoma (4.5 +/- 1.5 pmol/g wet weight, n = 11), Ganglioneuroblastoma (2.0 +/- 1.3 pmol/g wet weight, n = 4) and neuroblastoma (0.55 +/- 0.21 pmol/g wet weight, n = 3). The present study has shown that adrenomedullin is present in the human brain in high concentrations, suggesting that adrenomedullin acts as a neurotransmitter, neuromodulator or neurohormone in man.

  • neuropeptide y as a plasma marker for phaeochromocytoma Ganglioneuroblastoma and neuroblastoma
    Clinical Science, 1992
    Co-Authors: Toraichi Mouri, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Keiichi Itoi, Y Hayashi, Sumio Hasegawa, Yukio Miura
    Abstract:

    1. We investigated the usefulness of neuropeptide Y as a plasma marker for phaeochromocytoma, Ganglioneuroblastoma and neuroblastoma using a simple and highly sensitive r.i.a. for human neuropeptide Y. 2. Plasma immunoreactive neuropeptide Y concentrations were measured without extraction in plasma samples (100 microliters) from patients with various diseases. 3. The plasma immunoreactive neuropeptide Y concentration in patients with phaeochromocytoma (172.3 +/- 132.4 pmol/l, mean +/- SD, n = 23) was significantly higher than that in healthy adult subjects (40.1 +/- 10.1 pmol/l, n = 40, P < 0.0001). The plasma immunoreactive neuropeptide Y concentrations in patients with Ganglioneuroblastoma (590.7 +/- 563.6 pmol/l, n = 6) and patients with neuroblastoma (566.9 +/- 524.4 pmol/l, n = 15) were significantly higher than those in control children (1-9 years old, 82.2 +/- 39.9 pmol/l, n = 72, P < 0.0001). 4. The plasma immunoreactive neuropeptide Y concentration in patients with essential hypertension (34.0 +/- 3.7 pmol/l, n = 18) was within the normal range, but in patients with chronic renal failure undergoing maintenance haemodialysis (192.1 +/- 68.0 pmol/l, n = 25) and in non-dialysed patients with chronic renal failure (85.1 +/- 23.1 pmol/l, n = 7) it was significantly higher than that in healthy adult subjects (P < 0.0001). 5. Eighty-seven per cent of the patients with phaeochromocytoma, 67% of the patients with Ganglioneuroblastoma and 80% of the patients with neuroblastoma showed plasma immunoreactive neuropeptide Y concentrations higher than the upper limits in the control subjects [62 pmol/l (adult) and 160 pmol/l (children)].(ABSTRACT TRUNCATED AT 250 WORDS)

Masahiko Sone - One of the best experts on this subject based on the ideXlab platform.

  • expression of melanin concentrating hormone receptor messenger ribonucleic acid in tumor tissues of pheochromocytoma Ganglioneuroblastoma and neuroblastoma
    The Journal of Clinical Endocrinology and Metabolism, 2001
    Co-Authors: Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Fumitoshi Satoh, Yutaka Hayashi, Hironobu Sasano, Tomomi Kitamuro, Takao Noshiro, Shigeki Shibahara
    Abstract:

    Expression of melanin-concentrating hormone (MCH) receptor messenger ribonucleic acid (mRNA) was studied by RT-PCR and Northern blot analysis in human brain; pituitary; adrenal glands; tumor tissues of adrenal tumors, Ganglioneuroblastomas, and neuroblastomas; and various cultured tumor cell lines. RT-PCR analysis showed that MCH receptor mRNA was widely expressed in brain tissues, pituitary, normal portions of adrenal glands (cortex and medulla), tumor tissues of adrenocortical tumors (12 of 13 cases), pheochromocytoma (all 7 cases), Ganglioneuroblastoma (1 case), neuroblastoma (all 5 cases), and various cultured tumor cell lines (6 of 7 cell lines), including 2 neuroblastoma cell lines. Northern blot analysis showed the expression of MCH receptor mRNA (∼2.4 kb) only in the tumor tissues of 5 pheochromocytomas, 1 Ganglioneuroblastoma, and 4 neuroblastomas, indicating that the expression levels of MCH receptor mRNA are much higher in these tumors than in the other tissues. These findings raised the possib...

  • orexin a in the human brain and tumor tissues of Ganglioneuroblastoma and neuroblastoma
    Peptides, 2000
    Co-Authors: Zenei Arihara, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Fumitoshi Satoh, Sadayoshi Ito, Yutaka Hayashi, Hironobu Sasano, Toraichi Mouri
    Abstract:

    Regional distribution of orexin-A-like immunoreactivity in the human brain and pituitary, and the presence of orexin-A-like immunoreactivity in the tumor tissues of pheochromocytomas, Ganglioneuroblastomas and neuroblastomas were studied by radioimmunoassay. Expression of orexin mRNA was studied by reverse transcriptase polymerase chain reaction (PCR) method. Orexin-A-like immunoreactivity was detected in every region of human brain, but not in the pituitary. The highest concentration of orexin-A-like immunoreactivity in the human brain was found in hypothalamus (17.8 +/- 4.3 pmol/g wet weight, mean +/- SEM, n = 7), followed by thalamus, medulla oblongata, and pons. Orexin-A-like immunoreactivity was detected in the tumor tissues of Ganglioneuroblastoma and neuroblastoma, but not in the tumor tissues of pheochromocytoma. Reverse phase high performance liquid chromatographic analyses of the orexin-A-like immunoreactivity in the human brain extracts and neuroblastoma extracts showed a single immunoreactive peak, which was eluted in an identical position to synthetic human orexin-A. Orexin mRNA was expressed in the hypothalamus and in the tumor tissues of Ganglioneuroblastoma and neuroblastoma. These findings suggest that orexin-A is produced in the hypothalamus and transported to various brain regions via axons. In addition, this study has shown for the first time the production of orexin-A by Ganglioneuroblastomas and neuroblastomas.

  • cerebellin and cerebellin mrna in the human brain adrenal glands and the tumour tissues of adrenal tumour Ganglioneuroblastoma and neuroblastoma
    Journal of Endocrinology, 1997
    Co-Authors: Fumitoshi Satoh, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Yasuji Mizuno, Yukio Miura, Sadao Takase, Yutaka Hayashi
    Abstract:

    The expression of cerebellin and cerebellin mRNA was studied by radioimmunoassay and Northern blot analysis in the human brain, adrenal gland and the tumour tissues of adrenal tumour, Ganglioneuroblastoma and neuroblastoma. Immunoreactive cerebellin was detected in every region of brain studied, with the highest concentrations found in the hemisphere of the cerebellum (424.2 +/- 12.6 pmol/g wet weight, n = 6, mean +/- S.E.M.) and the vermis of the cerebellum (256.8 +/- 30.5 pmol/g wet weight). Immunoreactive cerebellin was also detected in the pituitary (8.2 +/- 1.8 pmol/g wet weight), the spinal cord (3.3 +/- 0.3 pmol/g wet weight) and the normal parts of adrenal glands (2.98 +/- 0.37 pmol/g wet weight, n = 9) and some tumour tissues, such as phaeochromocytomas, cortisol-producing adrenocortical adenomas, Ganglioneuroblastomas and neuroblastomas. Northern blot analysis showed that cerebellin mRNA was highly expressed in the hemisphere and vermis of the cerebellum. Cerebellin mRNA was also expressed in other regions of the brain and the tumour tissues of phaeochromocytoma, cortisol-producing adrenocortical adenoma, Ganglioneuroblastoma and neuroblastoma. Immunocytochemistry of the normal adrenal gland showed that immunoreactive cerebellin was localized in the adrenal medulla. The present study has shown the expression of cerebellin and cerebellin mRNA, not only in the cerebellum but also in other regions of the brain and some tumours, such as cortisol-producing adrenocortical adenoma, phaeochromocytoma and neuroblastoma. These findings suggest possible pathophysiological roles of cerebellin peptides, not only in the cerebellum, but also in the extra-cerebellar tissues.

  • adrenomedullin in human brain adrenal glands and tumor tissues of pheochromocytoma Ganglioneuroblastoma and neuroblastoma
    The Journal of Clinical Endocrinology and Metabolism, 1995
    Co-Authors: Fumitoshi Satoh, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Yukio Miura, Y Hayashi, Keishi Abe, Hironobu Sasano
    Abstract:

    Adrenomedullin is a potent vasodilator peptide that was isolated from human pheochromocytoma. But the presence of adrenomedullin in the brain has not been clarified. We studied the presence of adrenomedullin in the human brain obtained at autopsy from 6 subjects by radioimmunoassay, as well as in the human adrenal glands and tumor tissues of pheochromocytoma, Ganglioneuroblastoma and neuroblastoma. Immunoreactive adrenomedullin was detected in every region of human brain examined (0.26-1.4 pmol/g wet weight) with the highest concentrations found in thalamus (1.40 +/- 0.39 pmol/g wet weight, mean +/- SEM) and hypothalamus (1.28 +/- 0.48 pmol/g wet weight). Reverse phase high performance liquid chromatography showed that the immunoreactive adrenomedullin in the human brain was eluted in the position of synthetic human adrenomedullin 1-52. High concentrations of immunoreactive adrenomedullin were found in human adrenal glands (12.6 +/- 1.0 pmol/g wet weight, n = 7), pheochromocytoma (4.5 +/- 1.5 pmol/g wet weight, n = 11), Ganglioneuroblastoma (2.0 +/- 1.3 pmol/g wet weight, n = 4) and neuroblastoma (0.55 +/- 0.21 pmol/g wet weight, n = 3). The present study has shown that adrenomedullin is present in the human brain in high concentrations, suggesting that adrenomedullin acts as a neurotransmitter, neuromodulator or neurohormone in man.

  • neuropeptide y as a plasma marker for phaeochromocytoma Ganglioneuroblastoma and neuroblastoma
    Clinical Science, 1992
    Co-Authors: Toraichi Mouri, Kazuhiro Takahashi, Osamu Murakami, Kazuhito Totsune, Masahiko Sone, Makoto Ohneda, Keiichi Itoi, Y Hayashi, Sumio Hasegawa, Yukio Miura
    Abstract:

    1. We investigated the usefulness of neuropeptide Y as a plasma marker for phaeochromocytoma, Ganglioneuroblastoma and neuroblastoma using a simple and highly sensitive r.i.a. for human neuropeptide Y. 2. Plasma immunoreactive neuropeptide Y concentrations were measured without extraction in plasma samples (100 microliters) from patients with various diseases. 3. The plasma immunoreactive neuropeptide Y concentration in patients with phaeochromocytoma (172.3 +/- 132.4 pmol/l, mean +/- SD, n = 23) was significantly higher than that in healthy adult subjects (40.1 +/- 10.1 pmol/l, n = 40, P < 0.0001). The plasma immunoreactive neuropeptide Y concentrations in patients with Ganglioneuroblastoma (590.7 +/- 563.6 pmol/l, n = 6) and patients with neuroblastoma (566.9 +/- 524.4 pmol/l, n = 15) were significantly higher than those in control children (1-9 years old, 82.2 +/- 39.9 pmol/l, n = 72, P < 0.0001). 4. The plasma immunoreactive neuropeptide Y concentration in patients with essential hypertension (34.0 +/- 3.7 pmol/l, n = 18) was within the normal range, but in patients with chronic renal failure undergoing maintenance haemodialysis (192.1 +/- 68.0 pmol/l, n = 25) and in non-dialysed patients with chronic renal failure (85.1 +/- 23.1 pmol/l, n = 7) it was significantly higher than that in healthy adult subjects (P < 0.0001). 5. Eighty-seven per cent of the patients with phaeochromocytoma, 67% of the patients with Ganglioneuroblastoma and 80% of the patients with neuroblastoma showed plasma immunoreactive neuropeptide Y concentrations higher than the upper limits in the control subjects [62 pmol/l (adult) and 160 pmol/l (children)].(ABSTRACT TRUNCATED AT 250 WORDS)